Heerspink, H. J. L. Et Al. 2019. Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. The Lancet , vol.393, no.10184 , 1937-1947.

Heerspink, H. J. L., Parving, H., Andress, D. L., Bakris, G., Correa-Rotter, R., Hou, F., ... Kitzman, D. W.(2019). Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial. The Lancet , vol.393, no.10184, 1937-1947.

Heerspink, Hiddo Et Al. "Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial," The Lancet , vol.393, no.10184, 1937-1947, 2019

Heerspink, Hiddo J. Et Al. "Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial." The Lancet , vol.393, no.10184, pp.1937-1947, 2019

Heerspink, H. J. L. Et Al. (2019) . "Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial." The Lancet , vol.393, no.10184, pp.1937-1947.

@article{article, author={Hiddo J L Heerspink Et Al. }, title={Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial}, journal={The Lancet}, year=2019, pages={1937-1947} }